Bio-Rad Laboratories, Inc. (BIO) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $379.99 — A.R:R is negative (-2.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (4.1% away).
Bio-Rad Laboratories develops and sells instruments, reagents, and consumables across Life Science (40% of net sales) and Clinical Diagnostics (60% of net sales), with approximately 60% of net sales from international markets and Europe as the largest region. The company employs... Read more
Sell if holding. Analyst target reached at $379.99 — A.R:R is negative (-2.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (4.1% away). Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Score 5.0/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Oct 31, 2026Recent Developments — Bio-Rad Laboratories, Inc.
Latest news
- NEWS Bio-Rad Laboratories Q2 Earnings Call Highlights - TradingView — TradingView Oct 31, 2026 neutral
- NEWS Earnings Beat Could Be A Game Changer For Bio Rad (BIO) - Simply Wall St — Simply Wall St Oct 29, 2026 positive
- NEWS Bio-Rad Laboratories (BIO) Advances on Restructuring Plans and Margin Improvement Potential, Ariel Appreciation Fund Say — Yahoo Finance Oct 28, 2026 positive
- NEWS BIO Q3'26 Earnings: revenue estimate is 649.94M USD - TradingView — TradingView Oct 28, 2026 neutral
- NEWS Form 4 BIO-RAD LABORATORIES: Jonathan P. DiVincenzo (President & COO) For: 24 October - Investing.com UK — Investing.com UK Oct 28, 2026 neutral
Latest item Oct 31, 2026 · Generated 2026-11-05T11:59:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $379.99 — A.R:R is negative (-2.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (4.1% away). Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Prior stop was $356.37. Score 5.0/10, moderate confidence.
Analyst target $284.75 reached (−25.1% from $379.99); no take-profit level is published. Prior stop was $356.37. Stop-loss: $356.37.
Analyst target reached - limited upside remaining; Near 52-week high (4.1% away); Consecutive earnings misses (2).
Bio-Rad Laboratories, Inc. trades at a P/E of 48.2 (forward 39.0). TrendMatrix value score: 4.5/10. Verdict: Sell.
10 analysts rate BIO, with a consensus score of 3.5/5. 3 analysts publish price targets averaging $335.
What does Bio-Rad Laboratories, Inc. do?Bio-Rad Laboratories develops and sells instruments, reagents, and consumables across Life Science (40% of net sales)...
Bio-Rad Laboratories develops and sells instruments, reagents, and consumables across Life Science (40% of net sales) and Clinical Diagnostics (60% of net sales), with approximately 60% of net sales from international markets and Europe as the largest region. The company employs about 7,450 people in 37 countries and held a $5.7 billion Sartorius AG equity stake at December 31, 2025.